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We evaluate the CyberKnife (Accuray Incorporated, Sunnyvale, CA, USA) for non-invasive
delivery of accelerated partial breast irradiation (APBI) in early breast cancer patients.
Between 6/2009 and 5/2011, nine patients were treated with CyberKnife APBI. Normal
tissue constraints were imposed as outlined in the National Surgical Adjuvant Breast
and Bowel Project B-39/Radiation Therapy Oncology Group 0413 (NSABP/RTOG) Proto-
col (Vicini andWhite, 2007). Patients received a total dose of 30Gy in ﬁve fractions (group
1, n= 2) or 34Gy in 10 fractions (group 2, n= 7) delivered to the planning treatment vol-
ume (PTV) deﬁned as the clinical target volume (CTV) +2mm. The CTV was deﬁned as
either the lumpectomy cavity plus 10mm (n= 2) or 15mm (n= 7). The cavity was deﬁned
by a T2-weighted non-contrast breast MRI fused to a planning non-contrast thoracic CT.
The CyberKnife Synchrony system tracked gold ﬁducials sutured into the cavity wall dur-
ing lumpectomy. Treatments started 4–5weeks after lumpectomy. The mean PTV was
100 cm3 (range, 92–108 cm3) and 105 cm3 (range, 49–241 cm3) and the mean PTV isodose
prescription line was 70% for groups 1 and 2, respectively. The mean percent of whole
breast reference volume receiving 100 and 50% of the dose (V 100 and V 50) for group 1
was 11% (range, 8–13%) and 23% (range, 16–30%) and for group 2 was 11% (range, 7–
14%) and 26% (range, 21–35.0%), respectively. At a median 7months follow-up (range,
4–26months), no acute toxicities were seen. Acute cosmetic outcomes were excellent
or good in all patients; for those patients with more than 12months follow-up the late
cosmesis outcomes were excellent or good. In conclusion, the lack of observable acute
side effects and current excellent/good cosmetic outcomes is promising. We believe this
suggests the CyberKnife is a suitable non-invasive radiation platform for delivering APBI
with achievable normal tissue constraints.
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INTRODUCTION
The American Cancer Society estimated 192,370 new breast can-
cers were diagnosed in 2009 (Jemal et al., 2009). Due to a wide-
spread increase in mammography screening and improved imag-
ing technology,many of these tumors are found early and localized
to the breastwithnearly 25%presenting as ductal carcinoma in situ
(DCIS). Following a lumpectomy with clear margins (≥2mm),
90%of recurrences inwomenwhopresentwith early disease (stage
0, I, II) have been observed to occur within 10mm of the resection
cavity (Clark et al., 1992; Vicini et al., 2003, 2004). This observa-
tion has led to an enormous interest in accelerated partial breast
irradiation (APBI) for early breast cancer over the last decade.
Multi-catheter (King et al., 2000; Polgar et al., 2002; Benitez et al.,
2004) and balloon catheter brachytherapy (Cuttino et al., 2008;
Nelson et al., 2009;Vicini et al., 2011) initially paved the way. How-
ever, because of the invasiveness of these procedures, their steep
learning curve and risks of infection, lumpectomy cavity coverage
with three-dimensional conformal radiotherapy (3D-CRT), and
intensity-modulated radiotherapy (IMRT) have grown in popu-
larity. Unfortunately, these external beam techniques come with a
price: to assure coverage of amoving target beneath the ﬁxed beam
of a linear accelerator, the planning target volumes (PTVs) are
enlarged compared to brachytherapy volumes. This PTV increase
exposes more normal tissue to the effects of ionizing radiation.
Although a recent presentation at the ASCO Breast Cancer Sym-
posium reported that at a mean 36.7months less than 14% of
the 1,367 women enrolled in the 3D-CRT arm of the NSABP
B-39/RTOG 0413 trial had Grade 2 or 3 ﬁbrosis–cosmesis and
ﬁbrosis-deep connective tissue toxicities (Julian et al., 2010), other
institutions on a smaller scale have not been able to duplicate the
results and have published their concerns about poor cosmetic
outcomes (Hepel et al., 2009; Jagsi et al., 2010).
The CyberKnife (Accuray Incorporated, Sunnyvale, CA, USA)
offers an appealing APBI treatment option: non-invasive external
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beam radiation delivery mimicking the dosimetry of a breast
brachytherapy implant. A frameless robotic stereotactic radio-
surgery system, the CyberKnife provides image-guidance for con-
tinuous tracking of target motion with respiration and patient
movement (Kilby et al., 2010). This image-guided tracking system
allows treatments to bedeliveredwithout concerns of set-up repro-
ducibility or patient motion. As a result, the CyberKnife tracks
targets that move with respiration with great precision (Wong
et al., 2007; Hoogeman et al., 2009). Thus, using the CyberKnife
for APBI allows one to create a smaller PTV, resulting in less
radiation exposure to adjacent normal tissue and, potentially,
more agreeable cosmetic outcomes.Also,unlike brachytherapy, the
CyberKnife isodose volumes easily conform to irregularly shaped
cavities, are not impeded by air and ﬂuid pockets, and are easy
to constrain, thus limiting potential skin and chest wall injuries.
Indeed, researchers at the University of Texas Southwestern Med-
ical recently compared CyberKnife and 3D-CRT treatment plans.
They found that APBI treatment plans achieved highly conformal
target coverage and reduce the dose to nearby organs at risk relative
to 3D-CRT plans (Heinzerling et al., 2010). A treatment planning
study by Fox Chase reached similar conclusions for boost dose dis-
tributions produced for CyberKnife (Fan et al., 2010). Given these
potential beneﬁts, we present the technical set-up, physics plan-
ning, treatment, and early outcomes of nine patients who received
APBI using the CyberKnife.
MATERIALS AND METHODS
PATIENT SELECTION AND ELIGIBILITY
This is an IRB approved retrospective analysis of patients treated
with CyberKnife APBI at the Swedish Cancer Center. Patients eli-
gible for CyberKnife APBI were over 45 years of age with stage 0,
I, or IIA histologically conﬁrmed invasive non-lobular carcinoma
or DCIS. Axillary staging was not required for patients with DCIS.
Lesion size was required to be less than or equal to 3 cm and treat-
able by excision. Patients with inﬁltrating ductal carcinoma were
required to have a negative sentinel node sampling or axillary
dissection by routine histologic examination (H&E). A negative
pre-operative bilateral breastMRI was required to evaluate disease
extent and rule out additional disease foci in other parts of the
ipsilateral and contralateral breast. Additional eligibility criteria
following excision or re-excision included negative inked histo-
logic margins of at least 2mm or better. Negative post-excision
mammograms are required forDCIS tumors, if prior calciﬁcations
were seen. Patient exclusion criteria included invasive lobular or
multicentric carcinoma, pregnancy, histologically conﬁrmed pos-
itive axillary lymph nodes, collagen vascular disease, and tumors
that involved the skin or that had diffuse suspiciousmicrocalciﬁca-
tions on mammography. All patients were enrolled with initiation
of CyberKnife treatment within 42 days of last breast surgery.
Patients seen in consultation by a radiation oncologist, refused
the National Surgical Adjuvant Breast and Bowel Project B-
39/Radiation Therapy Oncology Group 0413 (NSABP/RTOG)
protocol (Vicini and White, 2007) and elected APBI treatment
with the CyberKnife. A written informed consent was obtained
for each patient regarding radiation risks. In our series, all patients
except one were considered “suitable” or “cautionary” candidates
as outlined in the ASTRO consensus statement for APBI (Smith
et al., 2009). The one exception was 46 years of age at the time of
diagnosis and tested positive for a genetic mutation of breast can-
cer type 1 susceptibility protein (BRCA1). She received counseling
frommore than one physician and more than one institution that
the standard of care was whole breast irradiation. She was also
informed of her risks in developing future cancers of the breast,
ovaries, and colon.
TREATMENT PLANNING
Patients were treated in the supine position, head ﬁrst with their
arms at their side. During treatment, cavity motion was tracked
using the CyberKnife Synchrony system (Accuray Incorporated,
Sunnyvale, CA, USA). The Synchrony system uses a combination
of ﬁducials implanted around the resection cavity and light emit-
ting diodes (LEDs) placed over the ipsilateral breast, which are
tracked continuously using a CCD camera. The position of the
LEDs is correlated with the simultaneous position of the cavity
as revealed by the ﬁducials in orthogonal x-rays. Based on the
correlation between the position of the LEDs and the internal
ﬁducials, a correlation model predicts the location of the tumor
throughout the respiratory cycle and moves the treatment beam
to remain on target with the treatment volume. The system has
been shown in end-to-end phantom tests to be accurate to within
1.5mm (Muacevic et al., 2007; Wong et al., 2007).
For this study, four to ﬁve, 2-mm gold markers (manufacturer
NMPE: product number MT-NW-887-864) were used. In an ear-
lier unpublished technical communication from the CyberKnife
protocol development committee, itwas shown that the commonly
used titanium clips could not be tracked reliably on imaging when
they were superimposed over the bony structures of the spine,
humerus, or ribs. On the other hand, these bio-compatible small
gold markers, with a high atomic number, allow for good contrast
on imaging.
In 11 tumors, the ﬁducials were sutured into the cavity wall
by the breast surgeon at the time of lumpectomy. One marker
each identiﬁed the superior, inferior, medial, lateral, and deep
margin of the cavity. CyberKnife treatment planning was gen-
erally performed 3 days before treatment which was performed
4–5weeks post surgery. Published series show this time period has
the least amount of volume change in the seroma identifying the
lumpectomy cavity (Weed et al., 2004).
In one patient with bilateral tumors, interventional radiology
placed ﬁducials under CT guidance around the lumpectomy cavity
2weeks after lumpectomy on the contralateral side. In this case the
patient was not a candidate for 3D-CRT because the lumpectomy
cavity was located in the high axilla. In addition, this patient was
aggressively seeking APBI and not willing to undergo any other
treatment. Thus, while visualization of the lumpectomy cavity can
be difﬁcult under CT we believed this ﬁducial placement would be
acceptable given we perform CT/MRI fusion for treatment plan-
ning. Fiducial implantation proceeded with four needles that were
separately loaded, each with one ﬁducial. The ﬁducials were then
placed 5–10mm from the superior, inferior, medial, and lateral
cavity wall. Treatment planning was performed 1week after ﬁdu-
cial implantation to allow the ﬁducials to stabilize and tominimize
the risk of ﬁducial migration. The PTV was located in the tail of
the breast. At the time of treatment planning it was observed that
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due to the target’s lateral location, optimal coverage, and con-
formality of the PTV could not be achieved without depositing
excessive dose in the ipsilateral lung. The CyberKnife beam set
generated in the case of lateral and posterior breast tumor loca-
tions is limited due to geometric factors which prevent the creation
of lateral oblique tangential beams. As a result of all these factors,
the patient was encouraged and agreed to whole breast irradiation
treatment in place of APBI to one lumpectomy cavity site. The
site with ﬁducials implanted during surgery was treated with the
CyberKnife.
During the treatment planning process, ﬁducials were located
on a non-contrast CT scan of the thorax. If the lumpectomy cavity
was ill-deﬁned on CT, a non-contrast MRI of the ipsilateral breast
was obtained. Both scans were acquired in the treatment position
with the patient supine, arms at their sides. Patient’s torsos were
elevated from the CT scanner’s couch using a 2′′ Styrofoam board.
As a result, their arm position on the ipsilateral breast side was
more vertical, thus offering more solid angles for the CyberKnife
beams to aim at the tumor without intersecting the ipsilateral
arm. Care was taken to avoid breast/cavity deformation from the
position of the ipsilateral arm or the MRI breast coils. The same
support bra was worn for both imaging and treatment. All metal
clasps and wires from the bra were removed before the planning
scans were obtained. In addition, the MRI breast coils were sus-
pended above the breast using various foamy supports to avoid
deformation of the breast/cavity.
Late in our series we found that an alpha cradle better immo-
bilized the patient’s arm during simulation and treatment. The
decreased breast deformation and variability of the arm position-
ing resulted in more accurate CT–MR fusions. Also, faster patient
set-up times were achieved. Speciﬁcally, the 3- to 5-cm thick alpha
cradle,which is elevated on a Styrofoamboard, serves to elevate the
patient’s body and allows their arms to drop at their side below the
level of the chest. All subsequent patients (n = 4) were positioned
in the alpha cradle both during the simulation CT and treatment.
The CT images were started at the mandible and extended several
centimeters below the inframammary fold. The CT slice thickness
was 1.25mm.
For treatment planning, the CT scans and MRI images were
exported to the MultiPlan treatment planning software (Accuray
Incorporated, Sunnyvale, CA, USA) and fused. When an MRI was
used, the lumpectomy cavity was best delineated on the T2 axial
or STIR MRI images. The ﬁducials were best seen on the T2∗
gradient-echo sequence. Once the T2∗-CT registration transform
was obtained it was copied to the other MR sequences and used
in delineation, particularly to the STIR sequence which was con-
sidered the most useful. Often the cavity could not be outlined for
target identiﬁcation on the CT alone due to the adjacent breast tis-
sue density or artifact scatter from the ﬁducials. In such cases, both
of these issues were overcome with the MRI imaging capabilities
(Figure 1).
Based upon an α/β ratio of 4.6 Gy for breast cancer tumor
control, an α/β ratio of 3.4 Gy for late changes in the breast appear-
ance (Bentzen et al., 2008a,b), and encouraging data from Dr.
Silvia Formenti at New York University (Formenti, 2005) we ini-
tially selected a total dose of 30Gy delivered in ﬁve fractions.
Normal tissue dose constraints were imposed as outlined in the
FIGURE 1 | Example of MRI images and image fusion. (A)T2*
gradient-echo MRI image, yellow arrow denotes the ﬁducial markers. (B)
STIR MRI image showing resection cavity. (C,D) Axial and sagittal fused
images.
NSABP/RTOG Protocol (Vicini and White, 2007). Unfortunately
without published data to support the use of the stereotactic plat-
form in the treatment of APBI, patient accrual was slow due to
limited re-imbursement. As a result, a decision wasmade to follow
the NSAPB/RTOG protocol (Vicini and White, 2007) so that the
dose as well as the fractionation scheme was matched. However,
with a dose proﬁle more similar to that observed with the NSABP
brachytherapy arm than the 3D-CRT arm of the protocol, a sec-
ond decision had to be made to expand the excision cavity volume
(ECV) by 10 or 15mm. Of interest, the multi-catheter study arm
of the NSAPB/RTOG study uses a CTV deﬁned as an expanded
volume of the ECV by 15mm and in the single catheter arm this
was reduced to the ECV plus 10mm. Based upon evidence that
90% of tumor cells remaining after lumpectomy are within 10mm
of the cavity edge (Clark et al., 1992; Vicini et al., 2003, 2004) and
our experience with brachytherapy implants whereby we observed
minor ﬂuid and air pockets surrounding the device can prohibit
the balloon from fully compressing adjacent breast tissue, we ini-
tially choose a CTV deﬁned as the ECV+ 10mm. However, after
treating two patients with a CTV deﬁned as the ECV+ 10mm
and documenting the exceedingly small volumes for the ipsilateral
breast receiving the prescribed dose and 50% of the prescribed
dose, we elected to continue our series with expanded volumes of
15mm instead of 10mm.
Speciﬁcally, our patient population received either 30Gy in ﬁve
fractions (group 1) or 34Gy in 10 fractions (group 2) delivered to
the PTV. Treatment was typically performed every day or within
2weeks as needed based upon scheduling restrictions. The PTV
was deﬁned as the CTV plus a 2-mm margin. The 2-mm margin
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was added to accommodate for the possible tracking error of the
ﬁducials. The CTV itself was deﬁned as the lumpectomy cavity
plus a margin of either 10 or 15mm. For two patients in group 2,
the CTV was deﬁned as the lumpectomy cavity plus 10mm. For
all other patients the CTV was deﬁned as the lumpectomy cavity
plus 15mm. No additional volumes were considered necessary to
account for variability in day-to-day set-up or patient mobility.
All patient treatments were planned with sequential optimiza-
tion on theMultiPlan System (version 8.0/3.0). The dose distribu-
tion calculations were performed using the ray-tracing algorithms
with heterogeneity correction and the appropriate CT electron
density model. The result of dose calculation using this simple
algorithmwas validated in a couple of cases using theMonte Carlo
dose calculation algorithm available in version 3.5 of the treatment
planning system. Excellent agreement with less than 2% differ-
ence was observed for both algorithms. Dose volume histogram
(DVH) analyses were conducted to determine whether dose con-
straints established in the NSABP/RTOG trial could be met. In
considering the NSABP/RTOG dose constraints it is important
to understand that several of the NSABP constraints for 3D-CRT
are in terms of volumes whereas the radiosurgery constraints are
maximum point doses. Speciﬁcally, the contralateral breast, thy-
roid, skin, and chest wall are radiosurgery maximum point doses.
On a related issue, if we looked at the range of doses and volumes
within a constraint for CyberKnife versus 3D-CRT, the DVH for
CyberKnife would drop off faster for the lung, thyroid, and heart
(i.e., the volumes for the higher doses within the constraints are
extremely small). As a result we used the NSABP dose constraints
as a guide and have adapted the dose constraints as appropriate
for radiosurgery maximum point doses. Furthermore, depend-
ing on the location of the lumpectomy site, particularly for very
medial inner quadrant or lower inner quadrant lesions, higher
contralateral breast point doses and higher volumes of heart or
lung receiving the suggested dose as outlined in the national study
were accepted. Lastly, while we did not contour the arms as critical
structures, we did examine the arm dose for all patients during
treatment planning and veriﬁed suitable arm point dose. We have
now added contouring of the arms to our treatment planning
protocol.
FOLLOW-UP, TOXICITY, AND COSMESIS
Follow-up visits were conducted by the treating radiation oncol-
ogist 4 weeks and 6months after completion of treatment and
annually thereafter. At each visit, patients were asked to ﬁll out the
NSABP/RTOG Quality of Life Questionnaire (Vicini and White,
2007). Follow-up breastmammograms were obtained at 6months
then annually. Annual breast MRI’s start at 1 year post-treatment.
As a result, patients are being imaged every 6months. Toxicity was
assessed using the National Cancer Institute’s Common Terminol-
ogy Criteria for Adverse Events. Cosmesis was assessed using the
four-point cosmetic rating scale of the NSABP/RTOG protocol
(Vicini and White, 2007). Using this scale, an excellent outcome
was deﬁned as “minimal or no difference.” A good cosmesis was
deﬁned as “a slight difference.” Fair or poor was deﬁned as “obvi-
ous differences. . .involving a quarter or less of the breast” or “as
marked change. . .involving more than a quarter of the breast
tissue,” respectively.
RESULTS
PATIENTS
Ten patients with 12 early breast cancers were planned for treat-
ment using CyberKnife APBI. Table 1 provides a summary of
patient and tumor characteristics for the treated patients. Two
patients had bilateral tumors. Of these two patients, one patient
with DCIS had a tumor less than 2mmwithout necrosis and clear
margins; this patient elected no treatment to that site other than
close observation. For the second bilateral breast cancer patient,
whole breast irradiation was used to treat an inﬁltrating ductal
carcinoma located in the tail of the breast. As described above,
this tumor site location posed a difﬁcult target to reach with
the CyberKnife without including beams that entered or exited
through the ipsilateral lung.
At the time of treatment, the ﬁducials in two patients were in
different positions relative to the cavity identiﬁed on the treatment
planning CT. In these patients, cavity volume reduction had
occurred as a result of ﬂuid absorption. In both patients, a second
set of scans including a CT and MRI was obtained and the targets
Table 1 | Patient and tumor characteristics for the nine patients with
nine treated tumors.
Characteristic Value
Age (years)
Mean 56
Range 46–68
Tumor type
DCIS 4
IDC 5
Tumor stage
Tis 4
T1a 1
T1b 1
T1c 3
Tumor size (cm) DCIS IDC
Mean 0.9 1.0
Range 0.4–1.8 0.5–1.5
Tumor laterality
Right 2 4
Left 2 1
Quadrant
UOQ 2 1
Central 0 3
LIQ 1 0
UIQ 1 1
Nodal stage
NX 4 –
N0 – 5
Other
Estrogen receptor positive 4 5
Chemotherapy after CyberKnife – 1
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; UOQ, upper outer
quadrant; UIQ, upper inner quadrant; LIQ, lower inner quadrant; NX, nodes were
not sampled in the four patients with DCIS.
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were re-planned with the treatment scheduled 2 days later. One of
these patients was able to be treated. However, the other patient’s
cavity continued to shrink and CyberKnife treatment was aborted
in favor of 3D-CRT. Consequently, nine patients completed APBI
using the CyberKnife.
DOSIMETRY AND TREATMENT
Patients received either 30Gy in ﬁve fractions (group 1, n = 2) or
34Gy in 10 fractions (group 2, n = 7) delivered to the PTV. In
addition to prescribing to a lower isodose than recommended in
the 3D-CRT arm of the national study, a ﬁeld within a ﬁeld was
created to force the high dose region into the ﬂuid ﬁlled lumpec-
tomy cavity. When 34Gy was prescribed to the PTV, the cavity
wall in most cases received less than 40Gy. During treatment
planning, DVH analyses were conducted to determine whether
dose constraint guidelines, as established by the NSABP/RTOG
trial, could be met. Tables 2 and 3 summarize the treatment vol-
umes for the patients in groups 1 and 2. Of note, the contralateral
lung dose and heart dose were higher than the NSABP 3D-CRT
guidelines and reﬂect the location of the lumpectomy cavity in
the breast. Similarly, two patients had an extremely medial cen-
tral and lower inner quadrant lumpectomy cavity resulting in a
point dose calculation from the DVH of 8 and 2Gy in the con-
tralateral breast. For the largest contralateral breast point dose
of 8Gy, the volume of the breast that received 0.5Gy was only
1.5%. For these patients we evaluated radiation treatment alterna-
tives (3D-CRT or tangents) and concluded that dose to the heart,
lung, and contralateral breast could be higher for 3D-CRT or tan-
gents. In addition, the contralateral lung receiving 1.7Gy in one
patient was 19% (NSABP guidelines <15%). This patient was an
outlier as the next largest volume was 6.5% and after that 1%.
Likewise, the heart receiving V1.7 in one patient with right sided
breast cancer was 19% (NSABP guidelines <5%). The next high-
est volumes were 10% for two patients and 6% for one patient;
all others were below 5%. As above, these numbers are reﬂec-
tive of the lumpectomy location in the breast. Lastly, one patient
received a 1.3-Gymaximum dose to the thyroid which was slightly
higher than the NSABP/RTOG protocol constraint of less than
1Gy.
For group 1, the mean number of beams was 155 (range, 112–
119) with a PTV isodose prescription of 70% for all patients.
For group 2, the mean number of beams was 157 (range, 143–
182) and the mean PTV isodose prescription was 70% (range,
64–80%). Figure 2 illustrates a typical treatment plan. The mean
PTV was 100 cm3 (range, 92–108 cm3) and 105 cm3 (range, 49–
241 cm3) for groups 1 and 2, respectively. The mean percentage
of a whole breast reference volume receiving 100 and 50% of the
dose (V 100 and V 50) was 11% (range, 8–13%) and 23% (range,
16–30) for group 1 and 11% (range, 7–14%) and 26% (range,
21–35%) for group 2, respectively. Using the CyberKnife G4 with
Iris (system version 8.5/3.5) the treatment time was approximately
60min.
TOXICITY, COSMESIS, AND OUTCOME
At a median follow-up of 7months (range, 4–26months), mini-
mal acute toxicities were observed. Speciﬁcally, half the patients
experienced minimal to moderate fatigue following treatment
Table 2 | Dose limitations for normal tissue based on the
NSABP-39/RTOG 0413, 3D-CRT protocol (Vicini andWhite, 2007) for
the patients in this series (n =2) that received CyberKnife APBI to a
total dose of 30Gy delivered in five fractions.
NSAPB/
RTOG structure
Constraint
(3D-CRT)
CyberKnife treatment
(mean, range)
Ipsilateral breast V 30 <35% Volume: 11%, 8–13%
V >15 <60% Volume: 23%, 16–30%
Contralateral
breast
Dmax <1Gy Max dose: 1Gy, 1–2Gy
Ipsilateral lung V 9 <15% Volume: 5%, 0–10%
Contralateral
lung
V 1.5 <15% Volume: 6%, 2–10%
Heart (RT breast) V 1.5 <5% NA
Heart (LT breast) V 1.5 <40% Volume: 40%, 25–54%
Thyroid Dmax <1Gy Volume: 1Gy: 0–1Gy
Skin Dmax <49.3Gy Max dose: <33Gy
Chest wall Dmax <40.8Gy Max dose: <30Gy
Note that the 3D-CRT constraints for contralateral breast, thyroid, skin, and chest
wall are volumes whereas for CyberKnife APBI they are maximum point doses.
Vx, volume of breast receiving x Gy; NA, not applicable.
Table 3 | Dose limitations for normal tissue based on the
NSABP-39/RTOG 0413, 3D-CRT protocol (Vicini andWhite, 2007) for
the patients in this series (n =7) that received CyberKnife APBI to a
total dose of 34Gy delivered in 10 fractions.
NSAPB/RTOG
structure
Constraint
(3D-CRT)
CyberKnife treatment
(mean, range)
Ipsilateral breast V 34 <35% Volume: 11%, 7–14%
V >17 <60% Volume: 26%, 21–35%
Contralateral breast Dmax <1Gy Max dose: 2Gy, 1–8Gy
Ipsilateral lung V 10 <15% Volume: 2%, 0–12%
Contralateral lung V 1.7 <15% Volume: 3%, 0–19%
Heart (RT breast) V 1.7 <5% Volume: 6%, 0–19%
Heart (LT breast) V 1.7 <40% Volume: 4%, 0–33%
Thyroid Dmax <1Gy Max dose: 0.2Gy, 0.0–0.6Gy
Skin Dmax <49.3Gy Max dose: 37.0Gy, 34.4–41.6Gy
Chest wall Dmax <40.8Gy Max dose: 36.0Gy, 29.2–39.9Gy
Note that the 3D-CRT constraints for contralateral breast, thyroid, skin, and chest
wall are volumes whereas for CyberKnife APBI they are maximum point doses.
Vx, volume of breast receiving x Gy.
lasting 2–3weeks. However, these patients reported the same level
of fatigue after surgery and at the start of their radiation. No skin,
muscle, or lung toxicities were observed. All patients had increased
breast edema following surgery; this became slightly worse after
SBRT. For four patients, the breast edema was clinically evident
2–4weeks after SBRT and resolved over 2months.
The size, shape, and texture of the treated breast was compared
to the breast’s original appearance after surgery and from pictures
taken at the time of treatment planning. Acute cosmetic outcomes
were excellent or good in all patients; for those patients with more
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FIGURE 2 | CyberKnife treatment planning images for a patient in the 34-Gy dose group. (A) Illustration of beam trajectories and (B) axial treatment
planning image illustrating the omission of high doses to the chest wall and skin. Shown in (B) are three isodose lines at the 70, 50, and 30%.The green
contour represents the planning target volume.
than 12months follow-up (n = 2) the late cosmesis outcomes
remained excellent or good. No patient’s cosmetic outcome was
graded as fair or poor. No breast cancer recurrence has been iden-
tiﬁed in this patient population to date. Figure 3 illustrates pre-
and post-treatment images.
DISCUSSION
Maturing data from the brachytherapy APBI experience indicate
early breast cancer recurrences are rare both locally and outside
the PTV (King et al., 2000; Vicini et al., 2001). Unfortunately,
brachytherapy is invasive, difﬁcult to perform, uncomfortable for
the patient, and carries an infection risk. On the other hand, 3D-
CRT and IMRT require larger treatment volumes for adequate
coverage of the PTV. The CyberKnife offers a dose proﬁle mimick-
ing brachytherapy without the large PTV requirement of 3D-CRT
and IMRT.Wepresent our early experienceswithCyberKnifeAPBI
in the treatment of nine early breast cancers. At amedian 7months
follow-up no patients have experienced fair/poor cosmesis and
none have recurred. While this study is limited by the small num-
ber of patients, limited follow-up and retrospective nature of the
study, the results to date are encouraging, but longer follow-up on
a larger patient population is necessary to conﬁrm the durability
of these results.
The increased PTV volumes in the NSABP trial are now being
challenged for compromising breast cosmesis (Vicini and White,
2007). Indeed, Jagsi et al. (2010) from the University of Michigan
reports unacceptable outcomes in their patient population receiv-
ing IMRT when the V 50 and V 100 was greater than 46 and 23%,
respectively. Both Jagsi andHepel, from Tufts University, conclude
that the NSAPB/RTOG trial’s normal tissue dose limitations result
in a larger than acceptable number of patients developing subcu-
taneous ﬁbrosis (Hepel et al., 2009; Jagsi et al., 2010). Both authors
further conclude that stricter dose volume limits are encouraged
for more agreeable outcomes. A more recent result from the Uni-
versity of Miami suggests that cosmesis is dependent on the target
volume (Lewin et al., 2011). Our target volume (100 and 105 cm3
for dose groups 1 and 2, respectively) resides between those of
the Jagsi study (185.8 cm3) and the University of Miami study
(71.44 cm3).
FIGURE 3 | Pre- and post-CyberKnife APBI mammograms. (A) A left
breast mammogram showing a biopsy clip in the tumor on a left lateral
medial (LLM) view. (B) A left medial lateral oblique view of the same patient
taken 14months after CyberKnife APBI showing four gold ﬁducials (round
opaque makers) and three titanium clips. The patient did not have
chemotherapy or hormonal therapy post-treatment.
In the NSABP/RTOG trial, the PTV evaluation (PTVeval) for
patients receiving 3D-CRT is 25mm or greater if penumbra is to
be considered to assure coverage of the 15-mmmicroscopic tumor
risk zone. Unlike the 3D-CRT coverage in the national trial, the
CyberKnife does not require the extra 10mm to compensate for
the variability in treatment set-up and breathing motion. In addi-
tion, the low prescription isodose and high number of treatment
beams used in CyberKnife APBI result in a smaller volume of nor-
mal tissue receiving a signiﬁcant dose. The PTV in our patient
series is similar to that seen in patients treated with multi-catheter
or balloon catheter brachytherapy. Speciﬁcally, the mean ipsilat-
eral breast volumes receiving 100 and 50% of the prescribed dose
(V 100, V 50) in our study was less than half that allowable in the
NSABP/RTOG study: 11 versus <35% and 26 versus <60% for
both groups 1 and 2 (see Tables 2 and 3). Patel et al. (2007) com-
pared the V 50 and V 100 of APBI with 3D-CRT verses interstitial
brachytherapy. They reported both to be signiﬁcantly larger for
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their patients’ receiving 3D-CRT than for the implant: 26 versus
12% and 52 versus 24%, respectively. Like the brachytherapy tech-
niques, CyberKnife APBI delivers a relatively steep dose gradient
outside and within the target volume with the dose maximum
placed within the ﬂuid cavity of the seroma. As such, we believe
that the small treatment volumes and steep dose gradients using
CyberKnife APBI will be responsible for more than acceptable
cosmetic results and low toxicity in the long-term.
CONCLUSION
Our experience suggests that the CyberKnife is a suitable non-
invasive radiation platform for delivering APBI with achievable
normal tissue constraints. Although the clinical outcomes for this
retrospective analysis are promising, the follow-up is too limited
and the number of treated patients is too small to permit ﬁrm
conclusions. Patient selection for APBI using the CyberKnife con-
tinues at our center and others worldwide including a recently
opened dose escalating Phase I trial at the University of Texas
Southwestern Medical Center (Timmerman, 2010). The next 3–
5 years will provide additional evidence for local control and
cosmetic outcomes in selected subgroups of patients with early
breast cancer.
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